Earnings Releases·Nov 10, 2026, 4:12 PM ET

Alto Neuroscience — Third Quarter 2026 Earnings Summary

Reported net loss of $25.1 million for Q3 2026, widening from $14.2 million in the prior-year period, driven by a 73% increase in R&D expenses to $18.2 million and G&A expenses rising to $9.1 million.
Cash position strengthened to $319.8 million as of September 30, 2026, following a July 2026 financing that generated $94.6 million in net proceeds, extending the runway to fund operations through 2030.
Management anticipates a milestone-rich 2027 with PACE-1 topline data expected in H2 2027, PACE-2 initiation pending FDA alignment in early 2027, and PACE-3 initiation expected in H2 2027.
Additional pipeline updates include ALTO-300 Phase 2b topline data in H1 2027 and ALTO-100 Phase 2b topline data in mid-2027, alongside the expansion of ALTO-207 Phase 3 development to include both monotherapy and adjunctive trials.